Press•October 13, 2026
Lexogen and Mithrl connect RNA-Seq library prep to AI-powered biological interpretation
Mithrl
Lexogen and Mithrl join forces: linking RNA sequencing high-quality data with traceable, evidence-backed biological interpretation in days instead of weeks.
VIENNA, AUSTRIA, October 13, 2026 /EINPresswire.com/ -- Lexogen, a specialist in RNA sequencing library preparation kits and services, today announced a partnership with Mithrl, the AI company building a world model for biology. The partnership takes RNA-Seq experiments from the bench to biological interpretation in one seamless workflow. Lexogen's Kangooroo data analysis platform, included with every Lexogen kit, now links directly to Mithrl-1: Mithrl's biomedical world model. Every Lexogen purchase comes with four weeks of free access to Mithrl-1.
RNA-Seq has become an affordable, widely used tool in disease research, drug development and personalized medicine. But generating data is no longer the slow step. Interpreting it is. Many labs wait weeks in a bioinformatics queue before they can act on results, and a fast answer is only useful if the data underneath it can be trusted.
“If the sequencing library is flawed, faster analysis only gets you to the wrong answer sooner,” said Stéphane Barges, CEO of Lexogen. “Lexogen has built its reputation on generating data that accurately reflects what is happening in the original biological sample, so we were very selective in choosing the right analysis partner. Mithrl combines two powerful capabilities: an AI co-scientist that helps researchers interpret their data, and a trusted knowledge base that relates those results to existing scientific evidence on diseases and biology. This combination is what makes Mithrl stand out. Together, we can now offer customers advanced AI-driven analysis alongside every Lexogen kit.”
“Lexogen has spent two decades solving the hardest part of RNA sequencing: getting the biology out of the sample intact,” said Vivek Adarsh, Co-Founder and CEO of Mithrl. “Its proprietary RNA sequencing library preparation methods make large expression studies both affordable and highly accurate. This is why so many demanding researchers trust Lexogen, and why our partnership is truly synergistic: an interpretation is only as good as the data behind it. Our customers now benefit from Lexogen’s world-class RNA sequencing technology providing a trusted foundation for every result. Together, scientists can go from a sequencing run to their next experiment in days.”
Availability
Mithrl-1 is available now to Lexogen Kangooroo users. Every Lexogen kit or service purchase includes four weeks of free access. To learn more, visit www.lexogen.com/kangooroo-ngs-data-analysis.
About Lexogen
Lexogen is an Austrian biotechnology company specializing in RNA sequencing and transcriptomics. Founded in Vienna in 2007, the company develops and manufactures proprietary RNA analysis technologies under ISO 13485 and in accordance with GMP guidelines, and provides ISO 13485-certified NGS services with designated workflows operated in compliance with GCLP principles. Widely recognized as the inventor of 3′ mRNA sequencing and for other innovations, Lexogen supports researchers worldwide with highly scalable NGS and bioinformatics solutions designed to deliver accurate, consistent and reliable data, including from very challenging and ultra-low-input samples, for research, drug discovery and clinical diagnostics.
For more information, visit www.lexogen.com.
About Mithrl
Mithrl is the AI infrastructure company for biopharma and life sciences R&D. At its core is Mithrl-1, a world model for biology that helps researchers interpret omics and other biomedical data and reach decisions faster. Scientists use Mithrl's AI agents, or build their own, to explore and analyze data in plain language, inside the tools and workflows they already use. Because Mithrl-1 is built for reproducibility, auditability and transparency, researchers can verify its results and act on them with confidence.
For more information, visit www.mithrl.com.
Contact information:
RNA-Seq has become an affordable, widely used tool in disease research, drug development and personalized medicine. But generating data is no longer the slow step. Interpreting it is. Many labs wait weeks in a bioinformatics queue before they can act on results, and a fast answer is only useful if the data underneath it can be trusted.
“If the sequencing library is flawed, faster analysis only gets you to the wrong answer sooner,” said Stéphane Barges, CEO of Lexogen. “Lexogen has built its reputation on generating data that accurately reflects what is happening in the original biological sample, so we were very selective in choosing the right analysis partner. Mithrl combines two powerful capabilities: an AI co-scientist that helps researchers interpret their data, and a trusted knowledge base that relates those results to existing scientific evidence on diseases and biology. This combination is what makes Mithrl stand out. Together, we can now offer customers advanced AI-driven analysis alongside every Lexogen kit.”
“Lexogen has spent two decades solving the hardest part of RNA sequencing: getting the biology out of the sample intact,” said Vivek Adarsh, Co-Founder and CEO of Mithrl. “Its proprietary RNA sequencing library preparation methods make large expression studies both affordable and highly accurate. This is why so many demanding researchers trust Lexogen, and why our partnership is truly synergistic: an interpretation is only as good as the data behind it. Our customers now benefit from Lexogen’s world-class RNA sequencing technology providing a trusted foundation for every result. Together, scientists can go from a sequencing run to their next experiment in days.”
Availability
Mithrl-1 is available now to Lexogen Kangooroo users. Every Lexogen kit or service purchase includes four weeks of free access. To learn more, visit www.lexogen.com/kangooroo-ngs-data-analysis.
About Lexogen
Lexogen is an Austrian biotechnology company specializing in RNA sequencing and transcriptomics. Founded in Vienna in 2007, the company develops and manufactures proprietary RNA analysis technologies under ISO 13485 and in accordance with GMP guidelines, and provides ISO 13485-certified NGS services with designated workflows operated in compliance with GCLP principles. Widely recognized as the inventor of 3′ mRNA sequencing and for other innovations, Lexogen supports researchers worldwide with highly scalable NGS and bioinformatics solutions designed to deliver accurate, consistent and reliable data, including from very challenging and ultra-low-input samples, for research, drug discovery and clinical diagnostics.
For more information, visit www.lexogen.com.
About Mithrl
Mithrl is the AI infrastructure company for biopharma and life sciences R&D. At its core is Mithrl-1, a world model for biology that helps researchers interpret omics and other biomedical data and reach decisions faster. Scientists use Mithrl's AI agents, or build their own, to explore and analyze data in plain language, inside the tools and workflows they already use. Because Mithrl-1 is built for reproducibility, auditability and transparency, researchers can verify its results and act on them with confidence.
For more information, visit www.mithrl.com.
Contact information: